Alex Arfaei trades his analyst's post for a new role as biotech VC; Sanofi vet heads to Vifor
Too often, Alex Arfaei arrived too late.
An analyst at BMO Capital Markets, he’d meet with biotech or pharmaceutical heads for their IPO or secondary funding and his brain, trained on a biology degree and six years at Merck and Endo, would spring with questions: Why this biomarker? Why this design? Why not this endpoint? Not that he could do anything about it. These execs were coming for clinical money; their decisions had been made and finalized long ago.
“There were so many times where I would be puzzled at the course of development,” Arfaei told Endpoints News. “More recently what a lot of companies would do is seek out my guidance and prioritize their projects accordingly.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.